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Summary
Nowadays, more than 90% of all children born with con-
genital heart disease (CHD) reach adult life. Although ini-
tially considered to be cured, the majority of them continue
to need specialised follow-up because they require re-
do interventions or are at increased risk of cardiovascular
complications and premature death. Arrhythmias are the
most common cause of unscheduled hospital visits for
grown-up CHD (GUCH) patients, accounting for one third
of emergency admissions in these patients. Some GUCH
patients are also at increased risk for sudden cardiac
death. The principles of arrhythmia management and the
prevention of sudden cardiac death in GUCH patients are
similar to those used in adults with acquired heart dis-
ease, but are not evidence based. Decompensated heart
failure is the other leading cause of death. Conventional
medical heart-failure therapy for left ventricular dysfunc-
tion is not effective in GUCH patients at highest risk of
heart failure, i.e., those with right or single ventricular fail-
ure. Careful haemodynamic assessment and structural in-
terventions are the first step to consider in GUCH patients
presenting with heart failure symptoms. Adults with mod-
erate or complex CHD and regular follow-up in specialised
GUCH centres have a survival benefit compared with pa-
tients without such follow-up. Cardiac surgery in GUCH
patients should be performed by surgeons trained in treat-
ment of CHD, i.e., surgeons also operating on paediatric
patients. A structured transition programme with a defined
transfer of care from the paediatric to the adult care en-
vironment is important to avoid lapses of care in today’s
adolescents with CHD. For GUCH patients with an inter-
vention performed decades ago and no specific cardiac
follow-up in later life, referral to a specialised GUCH cen-
tre is recommended and may save lives.
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Introduction
Cardiac defects are the most common birth defect and af-
fect approximately 0.8% of newborns [1]. In Switzerland,
every year approximately 700 children are born with con-
genital heart disease (CHD). Half of these children have
simple defects (e.g., a ventricular septal defect), the other
half have moderately complex (e.g., coarctation of the aor-
ta) or complex (e.g., transposition of the great arteries) de-
fects. Many of the simple defects close spontaneously dur-
ing the first years of life, but eventually 200 to 300 of the
infants with CHD will require an intervention.
Nowadays, more than 90% of children with repaired CHD
survive into adulthood [2]. The majority of them enter
adult life with the need for a lifelong specialised follow-up.
In the current era, the number of grown-up CHD (GUCH)
patients has outgrown the paediatric CHD cohort: two out
of three CHD patients are adults [3]. With further reduc-
tions in mortality resulting from advances in diagnostic
methods, cardiac surgery, catheter interventions and elec-
trophysiology, the prevalence of GUCH patients will con-
tinue to increase. It is estimated that currently 2.5 million
adults with CHD are living in Europe, of whom 20 000
in Switzerland [4]. The following review article highlights
historical milestones in CHD and the resulting challenges
GUCH patients have to face during their lifetime.
Historical background
The medical success story of CHD was strongly related to
pioneering work in cardiac surgery, and started with a pal-
liation procedure. In 1945, the John Hopkins’ surgeon Al-
fred Blalock performed a shunt operation in a 15-month-
old child with cyanotic heart disease and reduced pul-
monary blood flow. He sutured the left subclavian artery
end-to-side on the left pulmonary artery (fig. 1), with the
aim to increase pulmonary blood flow without the risk
of inducing shunt-related pulmonary hypertension. This
procedure, later called the Blalock-Taussig shunt, reduced
CHD mortality from 23 to 17% in older cyanotic children
[5]. In 1952, palliative procedures were succeeded by in-
tracardiac surgery. James Lewis closed an atrial septal de-
fect in a 5-year-old girl, using a special clamp technique
to avoid exsanguination of the beating heart. In 1955, John
W. Kirklin at the Mayo Clinic in Rochester reported the
successful use of a heart-lung machine and heralded the era
of open-heart surgery with use of extracorporeal circula-
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tion. However, the reported mortality for intracardiac cor-
rection of tetralogy of Fallot, the most common cyanotic
defect, was 39% with the heart-lung machine, substantial-
ly higher than the reported 17% mortality after palliation
with a Blalock-Taussig shunt [6]. The policy was adopted
to initially palliate complex defects by a shunt or banding
procedure with the aim to gain time and let the infants and
their cardiovascular structures grow, and thereby delay the
repair of the cardiac defect into early childhood (secondary
repair).
During the 1970s, a new intraoperative strategy was estab-
lished, consisting of cooling the patient to about 20°C on
the heart-lung machine, with subsequent cardiac arrest dur-
ing the repair operation, followed by rewarming prior to
weaning from the bypass. With this strategy, correction of
almost all cardiac anomalies was progressively mastered.
Further advances in surgical techniques and perioperative
care allowed a stepwise abandonment of secondary repair
strategies for primary repair, without the need for an ini-
tial palliation procedure. Even the most complex lesions,
such as a heart with a single ventricle due to hypoplasia of
one of the ventricles, can nowadays be approached (fig. 2)
[7]. Contemporary mortality in the first year of life for chil-
dren with non-severe CHD is now 2 to 4%, with an oper-
ative mortality of 0 to 2%. For children with severe CHD,
the corresponding mortality is 8 to 13%, with an operative
mortality of 4 to 6% [8]. Figure 3 depicts the remarkable
increase in survival rates with CHD over the past 70 years.
Figure 1: Blalock-Taussig-Shunt. Classic Blalock-Taussig shunt for
palliation of cyanotic heart disease due to reduced pulmonary
blood flow. The subclavian artery is sacrificed and increases blood
flow in the corresponding pulmonary artery, thereby increasing
systemic oxygen saturation.Illustration taken from http://www.chd-
diagrams.com. Creative Commons License Illustrations are li-
censed under Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International License by the New Media Center
of the University of Basel
Repaired does not mean cured
Although originally assumed to be curative, it was realised
over time that most interventions to treat CHD allowed
these children to grow up without severe physical limita-
tions, but with an – initially unexpected – increased long-
term morbidity and mortality, manifesting once these pa-
tients were in the midst of their adult life [10]. Figure 4
shows some of the factors contributing to the cardiovascu-
lar burden observed in GUCH patients. Table 1 lists com-
Figure 2: Fontan physiology. Modern type of Fontan procedure
(total cavopulmonary anastomosis with an extracardiac conduit)
for palliation of univentricular physiology, i.e. tricuspid atresia. De-
routing of systemic venous return directly to the pulmonary artery
avoids mixing of de-oxygenated and oxygenated blood in the func-
tional single ventricle, and unloads the heart. The original concept
was introduced by Fontan in 1971.Illustration taken from
http://www.chd-diagrams.com. Creative Commons License Illustra-
tions are licensed under Creative Commons Attribution-NonCom-
mercial-NoDerivatives 4.0 International License by the New Media
Center of the University of Basel.
Figure 3: Survival rates (first year) with congenital heart disease
(CHD) over different decades. The most remarkable increase in
survival was observed in children with complex CHD, from 20% for
children born in the 1950s to 90% for children born in the past 20
years [2, 9].
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mon heart defects and the expected complications in adult
life.
The increased morbidity and mortality risk is reflected by
a steadily growing number of re-hospitalisations within the
adult CHD population, out of proportion to the pure in-
crease in the population size over time [11]. Padrutt et
al. recently presented numbers for GUCH patients fol-
lowed up at the University Hospital Zurich: from 2005 to
2015, the number of adults under specialised care doubled,
and the frequency of patients requiring hospital admission
(e.g., for cardioversion) increased from 3.1 to 5.4% per
year, a relative increase of 75% [12].
The main reasons for hospital admissions in adult CHD
patients are supraventricular arrhythmias, lesion-specific
surgery or percutaneous interventions, decompensated
heart failure, ventricular tachycardias, the need for a pace-
maker, an intracardiac defibrillator (ICD) or other elec-
Figure 4: Factors contributing to the cardiovascular burden over
their lifetime in grown-up congenital heart disease (GUCH) pa-
tients. Prior to the repair procedure or intervention, the haemody-
namic consequences of the defect and hypoxaemia in cases of
cyanotic conditions pose an increased load to one or both ventri-
cles. Peri-interventional damage and residual lesions or sequelae
contribute to the cardiovascular burden after repair. Over time, ag-
ing and the emergence of acquired heart disease are an additional
source of increasing cardiovascular morbidity.
trophysiology procedures, pregnancy or delivery, evalua-
tion and treatment for pulmonary hypertension, infective
endocarditis and perioperative care for noncardiac surgery
[13, 14]. In addition, within the aging CHD population,
acquired morbidities (e.g., coronary artery disease, renal
failure, diabetes, liver dysfunction, endocrinological and
haematological disorders or cancer) are becoming impor-
tant outcome factors in conjunction with the underlying
congenital heart defect and add to the medical burden of
these patients [15]. Some of today’s adult patients also face
complications related to limited diagnostic possibilities in
the past. Screening blood products for the presence of he-
patitis C virus became routine only in 1992. Adults with
congenital heart surgery who received blood transfusions
before 1992 have a 5- to 20-fold increased prevalence of
hepatitis C infection [16].
Specialised care saves lives
Based on experience and outcome data, specialised care by
trained cardiologists of GUCH patients has been endorsed
and recommended by different national and international
societies within the last 20 years [4, 17, 18]. Minimal stan-
dards of care for GUCH patients in Switzerland are listed
in table 2.
Mylotte et al. observed a decline in GUCH mortality in a
province-wide database of Québec, Canada after the pub-
lication of the first Canadian GUCH guidelines in 1997,
which emphasised the importance of specialised care for
adults with moderate or complex cardiac defects [19]. In a
case-control analysis, referral to a specialised GUCH cen-
tre was associated with lower risk of death (odds ratio
[OR] 0.82, 95% confidence interval [CI] 0.68–0.97), in-
dependent of comorbidities, age and gender. Survival im-
provement was highest for patients with complex defects.
Several explanations are provided: the level of training and
experience of the healthcare providers in GUCH centres, a
Table 1: Late complications in common congenital cardiac defects.
Congenital heart defect type Possible complications / sequelae
1. Simple defects
Isolated small or repaired ventricular septal defect Arrhythmia, endocarditis
Small or repaired secundum atrial septal defect Arrhythmia
Mild pulmonary stenosis Endocarditis
Bicuspid aortic valve Endocarditis, ascending aortic dilation, valvular dysfunction
2. Moderately complex defects
Atrioventricular septal defects (native or repaired) Arrhythmia, atrioventricular block, endocarditis, heart failure, pulmonary hypertension
Large unrepaired secundum atrial septal defect or sinus venosus defect Arrhythmia, pulmonary hypertension, heart failure
Aortic coarctation (native or repaired) Systemic hypertension, local pseudoaneurysm or re-stenosis, cerebral aneurysm
Unrepaired anomalous pulmonary venous drainage Arrhythmia, pulmonary hypertension, heart failure
Repaired sinus venosus defect Arrhythmia, pulmonary hypertension
Ebstein’s anomaly (native or repaired) Arrhythmia, heart failure, endocarditis
Repaired tetralogy of Fallot Arrhythmia, heart failure, endocarditis
3. Complex defects
Implanted conduits (e.g., RV-PA conduit) Arrhythmia, endocarditis, heart failure
Repaired truncus arteriosus Arrhythmia, endocarditis, heart failure, pulmonary hypertension
Transposition of the great arteries
– After atrial switch procedure Arrhythmia, sinus node dysfunction, heart failure, pulmonary hypertension
– After aterial switch procedure Ostial coronary occlusion, right ventricular outflow tract obstruction, ascending aorta
dilatation, heart failure,
– Congenitally corrected transposition Arrhythmia, atrioventricular block, heart failure
Cyanotic heart condition, including Eisenmenger syndrome Arrhythmia, heart failure, endocarditis, paradoxical embolism / stroke, pulmonary hy-
pertension, gout, renal failure
Single ventricle after Fontan procedure Heart failure, arrhythmia, liver disease, protein loosing enteropathy, varicosis
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higher likelihood of use of practice guidelines and there-
fore less variability in care, the maximised use of medical
advances, and the availability of congenital cardiac sur-
geons. There is growing evidence that substantially lower
mortality rates (1.8 vs 4.8%) are achieved when a congen-
ital heart surgery team is operating on GUCH patients, i.e.,
a cardiac surgeon who also operates on children, and not
a “general” cardiac surgeon [20]. Currently, the Universi-
ty Hospitals of Lausanne/Geneva, Bern and Zurich provide
the optimal surgical environment to operate on GUCH pa-
tients in Switzerland. Cardiac surgery in GUCH patients
is characterised by a wide anatomical-clinical spectrum,
frequent multiorgan involvement, and the absence of ev-
idence-based data [21]. In contrast to cardiac surgery for
acquired heart disease, there is no validated surgical risk
score for GUCH patients [22]. All these factors enforce the
need for meticulous preoperative planning and preparation
of surgical interventions in GUCH patients, by a multidis-
ciplinary team with experience in CHD.
Transition and patient education
CHD patients and their families need to be aware of the
importance of uninterrupted specialised care. This requires
education and a structured transition and transfer process
in adolescence [23]. Studies on transfer destinations have
shown that without a structured transition, up to 75% of
adolescents with CHD are lost to follow-up once they
reached adult life [24]. This has important implications:
adults with CHD and a lapse of care are more likely to
be symptomatic at the time they are readmitted to a hos-
pital (OR 2.5, 95% CI 1–6), are more likely to have new
haemodynamic problems or an additional cardiac diagno-
sis (OR 9.6, 95% CI 4–23), and have a 3-fold (95% CI
2–7) greater likelihood of requiring urgent cardiac inter-
ventions [25]. Multiple efforts are necessary to keep pa-
tients on board [26]. Protective and risk factors for care
gaps in GUCH patients are presented in table 3. Organised
transition programmes providing education on the heart
defect, on healthy lifestyle, and coping and self-manage-
ment strategies are emphasised, [27]. A transition coordi-
nator is recommended to facilitate the transition process,
Table 2: Minimal standards of care for adolescents and adults with
congenital heart disease.
Transition – Transition process begins in
teenage years
– Structured transfer from paedi-
atric to adult care centre
Regular follow-up – Every non-simple repaired or
unrepaired defect should be pre-
sented once in a GUCH centre
– Individualised but lifelong regu-
lar follow-up is mandatory for all
non-simple lesions
Pregnancy – Prepregnancy counselling for
all women with CHD
– High-risk pregnancy managed
by a multidisciplinary team at
GUCH centre
Cardiac interventions – Expertise of a congenital car-
diac surgeon or congenital inva-
sive cardiologist mandatory
Non-cardiac surgery – Cyanotic patients, patients with
a systemic right ventricle or with
single ventricle physiology need
referral to specialised centre for
even minor surgery
CHD = congenital heart disease; GUCH = grown-up CHD patients
and nurses are predestined for this position. Fifteen to 60
min educational sessions led by nurses have shown to in-
crease patient’s CHD knowledge [28, 29].
Common cardiovascular problems in GUCH
patients
The need for lifelong medical follow-up is related to the
common cardiovascular complications seen in in GUCH
patients.
Arrhythmias and stroke
More than half of all GUCH patients with complex CHD
will develop arrhythmias by the age 65 years [30]. Ar-
rhythmias are the most common cause of unscheduled hos-
pital visits in adults with CHD and account for one third of
all emergency admissions in this population [31]. All types
of cardiac arrhythmias are prevalent, ranging from clini-
cally occult arrhythmias, such as silent atrial fibrillation,
to potentially fatal ventricular tachycardia. Table 4 illus-
trates the frequency of arrhythmia disturbances in differ-
ent congenital defects. Residual anatomic or haemodynam-
ic lesions and surgical scars from atrio- or ventriculotomies
form the substrate for arrhythmias or dyssynchrony [32].
GUCH patients are routinely advised to consult their pri-
mary physician in the event of persistent palpitations or a
sudden decrease in exercise capacity, in order to rule out
arrhythmias with a routine 12-lead ECG or Holter ECG.
Table 3: Predictors of care gaps in congenital heart disease patients.
Protective factors Risk factors
– Higher family income
– ≥ 1 comorbid condition
– Having a written referral to a
specialist GUCH centre
– Keeping first and second GUCH
appointment
– Patient’s belief that follow-up
should be performed at spe-
cialised clinic
– No substance use
– Compliance with antibiotic pro-
phylaxis
– Greater independence in at-
tending appointments
– Living independently
– Male gender
– Lower family income
– Travel distance to GUCH care
– Fewer outpatient visits in pae-
diatric care
– The last visit taking place out-
side a university hospital
– Childhood hospitalisations
– History of at least one missed
appointment
– Mild disease severity
– No previous heart surgery
GUCH = grown-up congenital heart disease patients
Table 4: Frequency of rhythm problems in GUCH patients.
Cardiac defect SVT VT SND AVB DYS
Ventricular septal defect
Secundum type atrial septal
defect
Primum type atrial septal de-
fect
Aortic coarctation
Ebstein’s anomaly
Tetralogy of Fallot
TGA with an atrial switch pro-
cedure
Single ventricle after Fontan
palliation
AVB = atrioventricular block; DYS = intraventricular dyssynchrony; SND
= sinus node dysfunction; SVT = supraventricular tachycardia; TGA
= transposition of the great arteries; VT = ventricular tachycardia The
shaded pattern ranges from minimal (no shading) to mild (light grey),
moderate (medium grey), and high (dark grey) risk. Adapted from
Khairy et al. [32].
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A particular challenge in CHD patients with supraventricu-
lar arrhythmias is the decision when to start oral anticoagu-
lation. Atrial fibrillation and intra-atrial re-entry tachycar-
dia are the most common arrhythmias, and are associated
with thrombosis and embolic events [33]. Among GUCH
patients, the stroke incidence is 9 to 12 times higher than
in the general population, particularly in younger adults
(below age 55 years). Important predictors of ischaemic
stroke, besides the absence of sinus rhythm, are the sever-
ity of the congenital defect, active infective endocarditis,
the presence of endovenous pacemaker leads, heart failure,
diabetes mellitus, and a recent history of myocardial in-
farction [33, 34]. The CHA2DS2-VASc score has proven
benefits in identifying patients with nonvalvular atrial fib-
rillation at increased risk for stroke, but has a limited abili-
ty in GUCH patients [35]. Anticoagulation is recommend-
ed by experts in all GUCH patients with atrial fibrillation
or intra-atrial re-entrant tachycardia and a history of previ-
ous intracardiac repair, cyanosis, after a Fontan palliation
or in the presence of a systemic right ventricle, indepen-
dent of the CHA2DS2 VASc score [36].
Sudden cardiac death accounts for 15 to 25% of fatalities
in GUCH patients [12, 37]. The incidence of sudden car-
diac death is in the range of 1 per 1000 patient-years, and
similar to the incidence of sustained ventricular tachycar-
dia in these adults [38]. Intracardiac defibrillators (ICDs)
are indicated in CHD adults for secondary prevention after
resuscitation from sudden cardiac death and in those with
spontaneous sustained ventricular tachycardia, after a care-
ful workup has failed to identify a clear reversible cause.
Selecting candidates for primary prevention is challenging.
In general, ICDs are recommended in patients with a sys-
temic left ventricular ejection fraction ≤35%, biventricular
physiology, and New York Heart Association (NYHA)
class II or III symptoms [38]. They may also be considered
in GUCH patients with a systemic right ventricular ejec-
tion fraction ≤35% and NYHA class III or IV, if additional
risk factors are present, such as a history of syncope, or
QRS duration >140 ms [39].
Heart failure
Beside sudden cardiac death, heart failure is the other lead-
ing cause of death in GUCH patients. Together, they ac-
count for nearly half of all late mortality in mixed cohorts
of children and adults [40, 41]. Mechanisms for heart fail-
ure in CHD are often lesion specific and may involve dif-
ferent pathophysiological pathways (table 5). Recognition
of heart failure symptoms can be delayed in GUCH pa-
tients because many have lived their entire life with the no-
tion of a limited exercise capacity, do not perceive changes
over time and underreport symptoms [42].
The Dutch CONCOR (CONgenital CORvitia Dutch na-
tional Registry) database reported an incidence of heart
failure admission in GUCH patients of 1.2 per 1000 pa-
tient-years, which was 10 times higher than the incidence
in the general population of adults of the same age [43].
GUCH patients admitted for heart failure had a 5-fold
higher mortality than CHD patients without heart failure
history, and the 1- and 3-year mortality after first heart fail-
ure admission were 24% and 35%, respectively. GUCH pa-
tients at high risk for heart failure are the ones with cardiac
defects affecting the right ventricle, i.e. corrected tetralogy
of Fallot, transposition of the great arteries with the right
ventricle in systemic position, Ebstein’s anomaly, or with a
single ventricle physiology.
Whereas medical heart failure treatment with beta-block-
ers, angiotensin converting-enzyme inhibitors or an-
giotensin receptor blockers, and aldosterone antagonists
have proven benefits in left ventricular heart failure, the
role of these agents has not been established in GUCH
patients with right or single ventricular dysfunction [44].
Whereas neurohormonal modulation is the cornerstone of
heart failure treatment in classic left heart failure patients
and invasive haemodynamic assessment is reserved for pa-
tients with refractory heart failure, the reverse is true for
most CHD diagnoses: careful haemodynamic assessment
and structural interventions are the first step to consider in
GUCH patients presenting with cardiac dysfunction [45].
Cardiac resynchronisation therapy has been used in a few
CHD patients, but data from small studies in heteroge-
neous CHD populations could not clearly determine which
GUCH patients will benefit, irrespective of anatomical dif-
ficulties for implantation [42]. Currently, the only estab-
lished therapy for end-stage heart failure in CHD patients
without pulmonary hypertension is heart transplantation
[46]. Although early post-transplant mortality is increased
in CHD patients, the 10-year survival is similar to non-
CHD transplant recipients [47]. Ventricular assist devices
can be used as a bridge to transplant [48]. Given the ubiq-
uitous shortage of donor organs and the number of GUCH
patients at risk, further medical options are currently being
investigated in adults with a systemic right ventricle [49].
Infective endocarditis
CHD patients are at increased lifetime risk of infective en-
docarditis [50]. The risk varies with the underlying de-
fect, but on average 1 in 1000 CHD patients suffers an
episode of infective endocarditis per year [51]. This in-
cidence is 20 to 30 times higher than the incidence ob-
served in the general population (3–5 cases per 100 000
patients per year). In contemporary GUCH cohorts, the
acute mortality of infective endocarditis is still 16%, and
1-year mortality is 19% [52]. Adults with repaired or palli-
ated pulmonary atresia and adults with corrected congeni-
tal transposition of the great arteries have the highest inci-
dence of infective endocarditis with 5.8 (95% CI 1.8–9.8)
and 2.3 (95% CI 0.5–4.1) cases per 1000 patient-years, fol-
Table 5: Pathophysiology of heart failure in grown-up congenital heart
disease patients.
Mechanism Example
Volume overload Long-sustained regurgitation of
native or repaired/replaced
valves, shunt lesions (residual
shunt, late diagnosis)
Pressure overload Valve or conduit stenosis, coarc-
tation, peripheral pulmonary
artery stenosis, systemic or pul-
monary hypertension
Ventricular anatomy Systemic right ventricle, function-
ally single ventricle
Myocardial injury Scars, cyanotic heart disease,
limited myocardial protection dur-
ing bypass, myocardial fibrosis
Coronary artery supply Coronary artery anomalies, coro-
nary artery disease
Myocardial architecture Ventricular non-compaction
Ventricular dyssynchrony Complete bundle-branch block af-
ter surgery, intractable arrhyth-
mias
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lowed by adults with a single ventricle, a bicuspid aortic
valve, and a ventricular septal defect. The risk is very low
in adults with a pulmonary stenosis or an atrial septal de-
fect, and almost non-existent in adults with a repaired or
still patent arterial duct. Besides the underlying cardiac
anatomy, the presence of prosthetic material also confers a
high risk of infective endocarditis. Among 14 000 GUCH
patients, biological or mechanical valves were indepen-
dently associated with infective endocarditis, in the short
and long term after implantation (0–6 months: hazard ratio
[HR] 17.29, 95% CI 7.34–40.70; 6–12 months: HR 15.91,
95% CI 6.76–37.45; after 12 months: HR 5.26, 95% CI
3.52–7.86), whereas valve repair carried only an increased
risk in the first 6 months following valve procedure (HR
3.34, 95% CI 1.33–8.41), but not thereafter [52].
Interestingly, infective endocarditis occurs less frequently
in women (odds ratio [OR] 0.5, 95% CI 0.4–0.7), inde-
pendent of the underlying defect or other risk factors [53].
Evidence supports a relationship between dental hygiene
and the risk of developing endocarditis-associated bacter-
aemia after daily events such as tooth-brushing [54]. A
large Swiss population study has shown that men are less
likely to practice good dental hygiene than women [55]. It
was shown that female gender and better disease knowl-
edge are strongly related to good dental hygiene in GUCH
patients [56], reinforcing the concept that patients’ educa-
tion plays an important role in endocarditis prevention, as
well as dental care. According to the current guidelines,
optimal oral health is considered more important for infec-
tive endocarditis prevention than prophylactic antibiotics
for dental procedures [57]. We discourage the empiric use
of antibiotic treatments for suspected bacterial infections
without evident focus, unless blood-cultures have been ob-
tained prior to starting antibiotic therapy.
GUCH and pregnancy
Many women with CHD are in childbearing age and con-
sider pregnancy [58]. From a cardiac point of view, preg-
nancy is a prolonged proarrhythmic and prothrombotic
state with increased cardiac output and decreased periph-
eral resistance. The majority of women with CHD, normal
biventricular function and no severe outflow tract obstruc-
tion tolerate pregnancy well. However, an impaired con-
tractile function (e.g., a systemic right ventricle), a fixed
obstruction (e.g., aortic coarctation, mitral stenosis, severe
pulmonary hypertension), mechanical valves, aortic dilata-
tion and residual cyanotic heart disease are conditions with
an increased risk for maternal cardiovascular complica-
tions during pregnancy and delivery [59]. Extremely high
risks of maternal mortality or morbidity are encountered in
women with pulmonary arterial hypertension of any cause,
severe systemic ventricular dysfunction with an ejection
fraction <30% or in functional NYHA class III or IV, se-
vere symptomatic mitral or aortic stenosis, native severe
coarctation, Marfan syndrome with an ascending aortic di-
ameter >45 mm or a bicuspid aortic valve with an ascend-
ing aortic diameter >50 mm, and in women with a histo-
ry of peripartum cardiomyopathy and residual impairment
of left ventricular function. If pregnancy occurs in these
situations, termination should be discussed. A multidisci-
plinary team of cardiologists, obstetricians and anaesthe-
siologists should monitor CHD patients before and during
pregnancy, delivery and the postpartum period. After de-
livery, cardiac output may take up to 6 months to return to
prepregnancy levels. Individual preconception counselling
of women with CHD concerning contraception, pregnancy
risks and inheritance is prerequisite to an informed deci-
sion.
End-of-life discussions and advanced care
planning
Death is not predictable in most CHD patients, and heart
failure symptoms may manifest late in the disease trajec-
tory, making early end-of-life discussions indispensable.
This includes the completion of advanced directives, pal-
liative care and resuscitation options, and identifying an at-
torney [60]. As in many other disciplines, advanced care
planning (ACP) discussions are rarely held with GUCH
patients. In a Canadian GUCH centre, out of 200 patients
only 2 (1%) recalled having discussed ACP, whereas 24
of 48 (50%) healthcare providers indicated that they dis-
cussed life expectancy, ACP and resuscitation preferences
regularly with their patients [61]. Patients’ preferences for
ACP did not depend on the CHD complexity, but health-
care providers stated that they discussed ACP more often
with patients with complex lesions. Similar results were
found in a recent survey of an American GUCH centre
[62]. Patients favour ACP discussions prior to a life-threat-
ening illness, but the physicians’ focus on life, rather on
death, hindered a timely initiation [63]. Adult CHD poses
many challenges, not only to patients, but also to their
treating physicians.
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